The US Food and Drug Administration (FDA) recently announced the approval of a ketamine-based nasal spray for treating depression. Ketamine is a strong sedative and dissociative that has been used in the veterinary and medical fields since the 1960s, but it has also been known as a club drug for nearly just as long. The fact that this medication is a nasal spray is a bit ironic, considering that the drug was often snorted when used at parties.
Numerous studies in recent years have shown that ketamine can be a good treatment option for major depression. Johnson & Johnson has developed a ketamine-based drug called esketamine, which has a slight chemical variation on the original substance. Once on the market, esketamine will be rebranded with the name Spravato.
Last month, an FDA panel voted 14-2 in favor of approving a nasal spray version of esketamine for cases of major depression where other medication has failed. The panel stipulated that patients would be required to have tried at least two other therapies before obtaining a prescription for esketamine.
Walter Dunn, who voted in favor of approval said:
“I think esketamine has the potential to be a game-changer in the treatment of depression … I use the term potential because the issues of cost and patient accessibility need to be addressed.”
Despite the overwhelming decision last month, it was unclear whether or not the FDA would actually take the advice of the panel and approve the medication due to the stigma associated with its illegal use.
Tiffany Farchione, M.D., acting director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said that the agency was impressed with how the drug performed in studies. In a press release Farchione said:
“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition. Controlled clinical trials that studied the safety and efficacy of this drug, along with careful review through the FDA’s drug approval process including a robust discussion with our external advisory committees, were important to our decision to approve this treatment. Because ofsafety concerns, the drug will only be available through a restricted distribution system and it must be administered in a certified medical office where the health care provider can monitor the patient.”
The FDA granted esketamine both Fast Track and Breakthrough Therapy designations.
According to the press release:
“The Spravato labeling contains a Boxed Warning that cautions that patients are at risk for sedation and difficulty with attention, judgment and thinking (dissociation), abuse and misuse, and suicidal thoughts and behaviors after administration of the drug. Because of the risk of sedation and dissociation, patients must be monitored by a health care provider for at least two hours after receiving their Spravato dose. The REMS requires the prescriber and the patient to both sign a Patient Enrollment Form that clearly states that the patient understands they should make arrangements to safely leave the health care setting to get home and that the patient should not drive or use heavy machinery for the rest of the day on which they receved [sic] the drug. Additionally, Spravato must be dispensed with a patient Medication Guide that outlines the drug’s uses and risks.
The patient self-administers Spravato nasal spray under the supervision of a health care provider in a certified doctor’s office or clinic, and the spray cannot be taken home. The health care provider will instruct the patient on how to operate the nasal spray device. During and after each use of the nasal spray device, the health care provider will check the patient and determine when the patient is ready to leave.”
Finish reading this article: